Jeong, Seung-Hyun
Jang, Ji-Hun
Lee, Yong-Bok
Funding for this research was provided by:
Handok Jeseok Foundation
National Research Foundation of Korea (RS-2023-00245453)
Article History
Received: 21 September 2023
Accepted: 4 December 2023
First Online: 16 December 2023
Declarations
:
: Clinical studies were conducted in accordance with the Rules of Good Clinical Practice and the revised Declaration of Helsinki for biomedical research involving human subjects.
: All participants provided written informed consent before participating in the bioequivalence and pharmacokinetic studies.
: All data were anonymized, and participants were informed that the results of this study may be subject to publication and presentation in meetings.
: The authors declare no competing interests.
: The clinical trial protocol was thoroughly reviewed and officially approved by the Ministry of Food and Drug Safety (Cheongju-si, Republic of Korea). The approval number of the trial was 100744, and the approval date was November 1, 2022. The clinical trial was conducted at the Bumin Clinical Trial Center (Seoul, Republic of Korea), and the total duration was from November 30, 2022, to December 9, 2022.